No Data
No Data
Arbutus Biopharma Faces Executive Changes Amid Legal Battle
Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?
Arbutus Biopharma's Strategic Restructuring and Legal Prospects Justify Buy Rating
Express News | Arbutus Biopharma Shares Are Trading Higher on Possible Continued Strength After the Company Reported a Year-over-year Increase in FY24 EPS Results on Thursday
Express News | Chardan Capital Maintains Buy on Arbutus Biopharma, Maintains $5 Price Target
Arbutus Biopharma Analyst Ratings